Algae Life Sciences now has 239 FDA-allowed structure/function claims for its AstaZine natural astaxanthin
AstaZine is produced in a 100% glass tube photobioreactor (PBR) closed system on the world’s second largest natural astaxanthin farm
Algae Life Sciences, a subsidiary of BGG, has announced that it now has 239 structure/function claims that have been allowed by the US FDA for its flagship product AstaZine natural astaxanthin.
AstaZine is the world’s first astaxanthin extracted from certified organic Haematococcus pluvialis microalgae. AstaZine is produced in a 100% glass tube photobioreactor (PBR) closed system on the world’s second largest natural astaxanthin farm.
'We’ve been working for months to attain this landmark achievement, which now makes us the leader in this critical marketing category,' said Bob Capelli, EVP of Global Marketing for Algae Life Sciences. 'We have some extremely compelling claims that are now allowed for AstaZine. This will enable brands to successfully market astaxanthin with an incredible variety of health claims. Individual brands can customise their message to consumers while educating them about astaxanthin’s extensive clinically validated health benefits.'
Chief Operating Officer Lixin Ding, PhD, added: 'Astaxanthin has been validated in approximately 500 different medical research studies to positively affect eye and brain health, improve skin appearance and quality, support joints and tendons, promote cardiovascular health, and provide various benefits for athletes and active people. And now with 239 allowed claims for labels and marketing literature, brands will easily and legally be able to tell US consumers just how beneficial Astaxanthin really is.'
AlgaeLife produces AstaZine in a variety of forms, including 5% powder; 5%, 10% and 20% oleoresin; 2% water soluble powder; 2.0% and 2.5% microencapsulated beadlets.
